- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Healthy high growth potential
Australian Pharmaceuticals & Biotech Healthy high growth potential
Results
4
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
4 companies
Immutep
Market Cap: AU$372.4m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.26
7D
6.3%
1Y
-16.4%
Clarity Pharmaceuticals
Market Cap: AU$1.4b
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
CU6
AU$4.19
7D
29.3%
1Y
-34.2%
PYC Therapeutics
Market Cap: AU$828.2m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.42
7D
4.4%
1Y
29.1%
Telix Pharmaceuticals
Market Cap: AU$8.5b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases.
TLX
AU$25.12
7D
5.5%
1Y
23.7%